Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.
about
Bortezomib for the treatment of multiple myelomaBortezomib for the treatment of multiple myelomaCancer-selective targeting of the NF-κB survival pathway with GADD45β/MKK7 inhibitorsUbiquitin-activating enzyme UBA1 is required for cellular response to DNA damageCell Proliferation in NeuroblastomaKnow the enemy as well as the weapons in hand: the aberrant death pathways and therapeutic agents in chronic lymphocytic leukemiaCathepsin B is a New Drug Target for Traumatic Brain Injury Therapeutics: Evidence for E64d as a Promising Lead Drug CandidateThe 26S proteasome is a multifaceted target for anti-cancer therapiesNatural killer cell biology: an update and future directionsα-Keto phenylamides as P1'-extended proteasome inhibitorsSystematic approaches to identify E3 ligase substratesStressing the ubiquitin-proteasome system without 20S proteolytic inhibition selectively kills cervical cancer cellsChemotherapy-induced neuropathies-a growing problem for patients and health care providersCombined chemical-genetic approach identifies cytosolic HSP70 dependence in rhabdomyosarcomaImproving drug discovery with high-content phenotypic screens by systematic selection of reporter cell linesIdentification of repurposed small molecule drugs for chordoma therapy.Label free fragment screening using surface plasmon resonance as a tool for fragment finding - analyzing parkin, a difficult CNS targetRAB7 counteracts PI3K-driven macropinocytosis activated at early stages of melanoma developmentSelective degradation of splicing factor CAPERα by anticancer sulfonamides.A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma.Regulation of PSMB5 protein and β subunits of mammalian proteasome by constitutively activated signal transducer and activator of transcription 3 (STAT3): potential role in bortezomib-mediated anticancer therapy.Towards Selective Mycobacterial ClpP1P2 Inhibitors with Reduced Activity against the Human Proteasome.Bortezomib Warhead-Switch Confers Dual Activity against Mycobacterial Caseinolytic Protease and Proteasome and Selectivity against Human Proteasome.Bortezomib treatment produces nocifensive behavior and changes in the expression of TRPV1, CGRP, and substance P in the rat DRG, spinal cord, and sciatic nerve.Leucovorin Enhances the Anti-cancer Effect of Bortezomib in Colorectal Cancer Cells.Sclareol inhibits cell proliferation and sensitizes cells to the antiproliferative effect of bortezomib via upregulating the tumor suppressor caveolin-1 in cervical cancer cells.Deubiquitinating enzymes as promising drug targets for infectious diseases.Novel panel of protein biomarkers to predict response to bortezomib-containing induction regimens in multiple myeloma patients.Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonismThe ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumorsMinireview: hey U(PS): metabolic and proteolytic homeostasis linked via AMPK and the ubiquitin proteasome system.Profiling human protein degradome delineates cellular responses to proteasomal inhibition and reveals a feedback mechanism in regulating proteasome homeostasis.Animal models and therapeutic molecular targets of cancer: utility and limitations.Rescue of murine F508del CFTR activity in native intestine by low temperature and proteasome inhibitorscMyc/miR-125b-5p signalling determines sensitivity to bortezomib in preclinical model of cutaneous T-cell lymphomas.Anti-CD70 immunocytokines for exploitation of interferon-γ-induced RIP1-dependent necrosis in renal cell carcinoma.Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321The quinone methide aurin is a heat shock response inducer that causes proteotoxic stress and Noxa-dependent apoptosis in malignant melanoma cells.Identification of Novel Proteasome Inhibitors from an Enaminone Library.
P2860
Q24185881-F678ED08-1A6B-4A32-BC49-AFD02BF38025Q24202774-81D9376E-B184-4A18-96EF-B27AE8DC3C28Q24305602-9F9724B2-5A5A-47B8-82DB-534C3154B673Q24310132-383E947F-3438-4BBD-A18A-02C07FC2E4DDQ26771708-ED713DE3-019C-4499-9808-C2196E204FBFQ26781895-8A31EF6A-0AF9-40E5-845D-43123AA4B1FEQ26782938-726F229A-A5B2-4900-A31C-819E7D8420F9Q26795764-78AE3404-A683-40B6-9112-82AD2A563A06Q26830512-6C3EAAFA-E30B-4A9C-BE9A-B2D36119A91FQ27694709-38A47AB6-5162-464F-BD26-3507DA0CFE4DQ28068398-F04A0638-B2AE-4161-AB0E-0C991714281AQ28476783-08DC7E8C-DC37-41C9-815E-B5038591DFE9Q28818565-04FF0D35-3B78-47E4-93CC-C0E7534D895CQ28830095-994D9275-22ED-483C-810A-27071536B72BQ28834223-4D2DD63F-E8AF-4C1E-8C7A-FBEF6D1ED4C4Q30417586-067DB8AE-CD19-44C1-9680-51D9B07899A0Q30452210-7D467B40-8CAD-49A8-8F52-7291DFAA7D8DQ30657002-09B3840A-9D76-4D71-BD08-D975F5BDE51BQ33112699-1A22041F-1675-4D56-A2F8-D3A237A912FAQ33427979-B0753EDB-7796-4426-91B7-0860D5D98B9DQ33556178-05C1EF79-27DE-432E-909A-5B60B695BEB8Q33601825-267E06C6-BDA7-454F-B443-94D787959B08Q33607221-78AB0152-A92D-4324-8860-2CBFDFDB6C17Q33617012-F220A3D1-C6DE-44E0-BC58-146CDB8F5772Q33677971-1F523090-56A3-4663-BF15-FC626BEA5A3FQ33702153-6CE96980-70AE-42D0-AB11-06A051D8C082Q33836097-AC879090-02DD-451B-A9D0-9C6F15120874Q33887173-A2FFAF60-15CA-467C-BD97-3AB4E8DFA8E5Q34079481-DF770369-F0FF-4495-9218-A7205838BDBEQ34218976-808C8A55-D5BE-4DBA-9AB2-4A9E6AAAA334Q34265028-F379BDB3-E897-4A2C-9787-E919519C6B30Q34289909-BBAD01A6-7610-43F1-91DC-0DB87AE51FA4Q34386828-B494C89A-B624-45E2-AD16-B5C8C9066618Q34532897-F69F54FF-8379-47E2-BCFB-27CB66BA1FEEQ34635116-A57A4D04-D3A5-473B-83EB-975064BC57D6Q34684399-AC7943F7-27DC-4F32-B848-45471C3D3326Q34788381-452C6439-6C24-42D9-B41B-E18C01844347Q35058595-9FD40790-D647-469A-A86E-524F7CC9ACA4Q35121301-F301BF92-2AC8-4494-BE11-D6BE1CFC2325Q35508457-D016A24A-EAC8-4FD4-9EDE-C2187ADE80B0
P2860
Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Bortezomib as the first protea ...... tatus and future perspectives.
@ast
Bortezomib as the first protea ...... tatus and future perspectives.
@en
type
label
Bortezomib as the first protea ...... tatus and future perspectives.
@ast
Bortezomib as the first protea ...... tatus and future perspectives.
@en
prefLabel
Bortezomib as the first protea ...... tatus and future perspectives.
@ast
Bortezomib as the first protea ...... tatus and future perspectives.
@en
P2093
P2860
P1476
Bortezomib as the first protea ...... tatus and future perspectives.
@en
P2093
P2860
P304
P356
10.2174/156800911794519752
P577
2011-03-01T00:00:00Z